Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Sheraton Boston Hotel

Aug 14, 2017 7:30 AM - Aug 17, 2017 5:00 PM

39 Dalton Street, , Boston, MA 02119 , USA

Regulatory Affairs: The IND, NDA, and Postmarketing

Back to Agenda

Session 20: Post-NDA Approval Regulatory Requirements

Session Chair(s)

Elliott Berger, PhD, MS

Elliott Berger, PhD, MS

President

ETB Regualtory Consulting, United States

Post-NDA approval obligations
Postmarketing (Phase 4) requirements and commitments
Supplements and other changes to an approved application
Postmarketing reporting of adverse drug experiences
15-Day Alert Reports
NDA Annual Reports
NDA Field Alert Reports
Biologic Product Deviation Reports
Drug registration and listing

Have an account?